The Nexus Team
Nexus is managed by Principals who are supported by Advisors and affiliates in Quincy (MA), San Francisco, London, Munich, Geneva and Tokyo. The Principals and Senior Advisors possess more than 60 years of private equity investment experience between them as well as entrepreneurial and operating success in our target industries.
The backgrounds of the Principals include technical education and operating experience, successful careers in line management of both established and emerging companies, serving on boards of directors of both public and private companies, and private and public company equity analysis. During their careers, the Nexus team members have managed over $1billion.
The Principals also have exceptional track records as hands-on investors in adding value to their portfolio companies through strategic guidance, introductions to sources of capital, technology, strategic partners and acquirers, and active participation in assembling the teams and resources necessary for success.
Jump to: Principals | Senior Advisors | Advisors
Gregory F. Zaic, Principal
Greg has over 27 years of venture capital investment experience, having played a leadership role in the management of a number of venture capital funds. He currently represents Nexus on the Boards of Aethon, Kiyatec and Zipit Wireless. Greg also represented Nexus as a director of Sabal Medical and Cutanea Life Sciences until he negotiated their sale to a European and Asian acquirer respectively. In the past, he has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, organizational development, and becoming successful publicly traded companies. Selected investments include Biodel (novel insulin formulation, IPO), PerSeptive Biosystems (protein separation systems, acquired by Perkin Elmer) and Infusion Systems (disposable IV pump, acquired by Baxter).
Prior to joining Nexus, Greg was a general partner of Prince Ventures, a healthcare- focused, venture capital partnership. During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, the leader of Vista's health care practice, and Bob Fleming, Vista's IT partner. From 1972 until 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter's total profits.
Greg received a BS in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering the Massachusetts Institute of Technology (MIT); and an MS from MIT's Sloan School of Management.
Thomas E. Hancock, Principal
Tom has nearly 20 years of venture capital experience and securities analyst experience. He represents or has represented Nexus on the Boards of Presidio Pharmaceuticals, SpectraAnalysis, EyeGate Pharmaceuticals, MyoScience and Magellan Biosciences. Over the last several years, Tom has led investments in numerous successful private companies, including Panacos Pharmaceuticals and Atricure.
Prior to joining Nexus, Tom was a Managing Director and Senior Equity Analyst at U. S. Bancorp Piper Jaffray covering publicly traded biopharmaceutical companies and drug discovery supplier companies. While at Piper, he published research notes, reports, industry overviews and technology updates for the benefit of the investment community on Gilead Sciences, Tularik, Human Genome Sciences, Millennium Pharmaceuticals, Applied Biosystems, Charles River Laboratories, Invitrogen and Millipore, among others. Tom also participated in the identification, analysis and recommendation of many companies both pre- and post-IPO. Previously, he was Senior Analyst at Leerink Swann & Company, published equity research on public biopharmaceutical companies including Genentech, Biogen, Amgen and Vertex Pharmaceuticals, among others. Tom was a Senior Research Associate at NationsBanc Montgomery Securities as well as worked in the business development group at Genentech. He was a research scientist at Cor Therapeutics and Genentech.
Tom holds a B.S. degree in molecular biology and an MBA, both from the University of California, Berkeley.
Edwin Snape, PhD
Ed has over 35 years of experience in founding, investing in, and guiding the development of many public and private healthcare and specialty materials companies. Ed helped to create Nexus Medical Partners in 2004 and guided its evolution into the present Nexus NMT Capital. Ed continues to work with Nexus as a Senior Advisor. He is currently on the boards of Selah Genomics (molecular diagnostics), Deltex Medical (AIM-listed intra-operative esophageal monitoring) and Spectra Analysis Instruments (FTIR spectroscopy)
Prior to Nexus, Ed was Managing General Partner of The Vista Group, a leading east coast venture capital firm; Chairman of Orien Ventures, a private equity firm with Pacific Rim affiliations; and a Director of the Cygnus Funds, two U.K.-based private equity firms specializing in investments throughout Europe. He was also a founder of an ASEAN Fund based in Indonesia. For these and other funds, Ed served on the Board of Directors and was a guiding force in the development of numerous successful companies. Many of these became highly successful public entities.
Earlier in his career, he founded and developed the Liposome Company, which became public and was later sold to Elan Corporation for over $700 million. Ed also founded and developed Ergenics, a pioneer in applying metal hydrides for batteries, energy conversion, and transportation. He was also a principal of International Nickel's venture capital arm that made initial stage investments in both Genentech and Biogen. He was also involved in the initial venture capital financing for Emulex Corporation.
Ed holds several patents in the advanced materials field where he has pioneered various technological innovations and authored numerous technical papers. He has been a recipient of several awards in the material sciences industry, including the AB Campbell Award and the Hunt Silver Medal.
Ed received BS and PhD degrees in metallurgy from Leeds University, England.
John F. Rousseau, Jr.
John has over 30 years of experience in investment management, corporate operations and legal practice. He has been active in guiding a variety of companies, as board member, investor and counsel, in all stages from start-up to being public. He has led investments in a variety of healthcare companies focused in the fields of medical devices, biotechnology, diagnostics, medical instruments and healthcare services. He is co-founder of Nexus Medical Partners, a private equity firm specializing in medical technology and life science investments in the US and Europe, which has evolved into Nexus NMT Capital. Investments with which he has been directly involved and which became public have included Harvard Bioscience (Nasdaq:HBIO), Santarus (Nasdaq:SNTS), ActriCure (Nasdaq:ATRC) and Minrad International (AMEX:BUF). He has served as a Director of several portfolio companies, and currently serves on the boards of Spectra Analysis Instruments; NuvoLase, which has developed and is selling the first FDA-approved laser treatment of onychomycosis; and Seleh Genomics, specializing in molecular diagnostics and next generation sequencing to advance personalized medicine.
Earlier in his career, John held the operating positions of Senior Vice President, Homart Development (a Sears Roebuck subsidiary); Senior Vice President, Spaulding & Slye Company and Chief Executive Officer, Associated Project Control. Prior to beginning his business career, he practiced law for fifteen years, specializing in tax, development and corporate finance transactions with firms in New York, Geneva and Boston, where he was a Senior Partner with the law firm of Hale & Dorr (now Wilmer Hale). John holds a B.A. from Amherst College and a J.D. from Columbia Law School.